AndroFeme vs Testogel: understanding your testosterone options during menopause
As awareness of menopause care continues to grow in the UK, more women are beginning to ask broader questions about hormonal health, including whether testosterone may have a role in supporting certain symptoms.
Recent reporting has highlighted a rise in testosterone prescriptions for women, reflecting increasing recognition that menopause symptoms can be complex, individual and, for some women, not always fully addressed by “standard” HRT alone.
For women experiencing persistent low sexual desire that is causing distress, testosterone may sometimes be considered as part of a carefully assessed treatment plan.
Yet many women remain understandably unsure about what testosterone treatment involves, what options are available, including treatments such as AndroFeme compared with Testogel.
At Jaya Life, menopause care is centred around informed, evidence-based support, helping women understand their options clearly, calmly and in partnership with experienced clinicians.
Why might testosterone be prescribed during menopause?
According to current NHS and British Menopause Society guidance, testosterone may be considered for menopausal women experiencing low sexual desire (hypoactive sexual desire disorder) when this is causing distress and when standard HRT alone has not been sufficient.
It’s important to note that testosterone is not routinely prescribed for all menopause symptoms, and it is not considered a first-line treatment for concerns such as fatigue, mood or brain fog alone.
For women who may benefit, testosterone is typically offered as one part of a broader menopause treatment plan, with appropriate blood testing, symptom review and ongoing clinical monitoring.
Testogel: the more familiar option
For many years, Testogel has been one of the testosterone products most commonly prescribed for women in the UK.
Although originally licensed for men, it has been widely used ‘off-label’ by menopause specialists in carefully adjusted lower doses for women. It is not licensed to be used in women but is commonly used by menopause specialists, in private clinics and in the NHS.
This means:
It is already relatively familiar to many clinicians
It may be available through some NHS or private prescribing pathways
Many women have used it successfully under specialist supervision
Because Testogel was not specifically designed for female dosing, however, some women may find measuring very small doses slightly less straightforward.
For some, this is manageable. For others, a female-specific product may feel simpler.
AndroFeme: a newer female-specific option
AndroFeme represents an important step forward in women’s hormone care.
As the first testosterone cream licensed specifically for women in the UK, it has been developed with female dosing requirements in mind, offering:
Dosing designed specifically for women
More straightforward administration for some patients
A formulation tailored to female therapeutic use
For many women and clinicians, this may offer added reassurance or convenience.
However, as with many newly approved treatments, availability may vary initially, and access may be more common through private menopause services before broader NHS prescribing becomes more established.
Is one better than the other?
For most women, the answer is not necessarily. Both Testogel and AndroFeme may be appropriate options when prescribed safely and monitored properly.
The right choice will depend on factors such as:
Individual symptoms
Medical history
Blood test results
Treatment access
Cost
Personal preference
For some women, an established option like Testogel may continue to work well. For others, AndroFeme may feel easier or more tailored.
Menopause care is rarely one-size-fits-all, and testosterone treatment is no exception.
Why clinical guidance matters
As conversations around testosterone become more visible online, it can be tempting to view it as a universal solution. But hormone care works best when it is personalised and carefully monitored.
At Jaya Life, this means:
Individualised symptom assessment
Evidence-based prescribing aligned with BMS and NHS guidance
Regular blood monitoring
Ongoing review of benefits and side effects
Clear conversations about access, expectations and cost
Because good menopause care is not about following headlines, it’s about finding the safest, most appropriate approach for each woman.
The bottom line
As more women explore testosterone as part of menopause care, understanding the difference between products such as Testogel and AndroFeme can help support informed conversations with qualified healthcare professionals.
Testogel remains an established and widely used option. AndroFeme offers a newer, female-specific alternative that may expand treatment choice.
Neither is automatically better, the most important factor is that treatment is evidence-based, clinically supervised and tailored to your needs.
At Jaya Life, we believe women deserve menopause care that feels informed, balanced and personal.
Because hormonal health should never feel like guesswork.
